Gordon M. Keller is a Canadian scientist recognized for his research on applying developmental biology findings to in vitro pluripotent stem cell differentiation. He is currently a Senior Scientist at the Ontario Cancer Institute, a Professor at the University of Toronto and the director of the McEwen Centre for Regenerative Medicine.[3]
Gordon Michael Keller[2] | |
|---|---|
| Born | November 1952 Melville, Saskatchewan, Canada |
| Nationality | Canadian/American |
| Alma mater | University of Alberta University of Saskatchewan |
| Known for | In vitro directed differentiation of pluripotent stem cells |
| Awards | 25 Transformational Canadians Canada Research Chair Ogawa-Yamanaka Stem Cell Prize (2019)[1] |
| Scientific career | |
| Fields | Stem cell biology, Developmental biology |
| Institutions | McEwen Centre for Regenerative Medicine University of Toronto University Health Network Ontario Cancer Institute University of Alberta, Ph.D. |
Biography
editKeller was born in 1952 in Melville, Saskatchewan[4] and was raised on a farm.[5] He completed his Bachelor of Science at the University of Saskatchewan.[6] He completed his PhD in Immunology at the University of Alberta in 1979, and completed his postdoctoral fellowship with the Ontario Cancer Institute in 1983. He then began his career in Switzerland and Austria. In 1990, he moved to the United States. Initially, Keller was at the National Jewish Centre for Immunology and Respiratory Medicine in Denver, CO and later moved to the Mount Sinai School of Medicine in New York City, NY. In 2007, Keller returned to Canada to assume his current role and established his laboratory at the MaRS Centre/Toronto Medical Discovery Tower.[2] In 2016, Keller co-founded Toronto-based BlueRock Therapeutics with Lorenz Studer for the development of iPSC-derived cells for clinical transplantation.
Scientific research
editIn 1997, Keller's team was the first to successfully isolate the developmentally significant hemangioblast—a multipotent precursor cell that can differentiate to the hematopoietic and endothelial cell fates—using embryonic stem cell technology.[7]
Currently, the Keller group's research includes the differentiation of pluripotent stem cells to the endodermal lineage: hepatocytes,[8] cholangiocytes and pancreatic progenitors;[9] as well as to mesodermal cell fates: cardiomyocytes,[10] chondrocytes,[11] T lymphocytes[12] and myeloid precursors.[13]
Honours
editKeller holds a Tier I Canada Research Chair in Embryonic Stem Cell Biology (2013-2020).[2] He serves on the Scientific Advisory Boards of the Centre for Commercialization of Regenerative Medicine and Stemgent, and is also a founding member and past president (2005-2006) of the International Society for Stem Cell Research.[2] In addition, he is a senior editor for the journal Development.[14]
References
edit- ^ Langelier, Julie (July 31, 2019). "The 2019 Ogawa-Yamanaka Stem Cell Prize Awarded to Gordon Keller". gladstone.org.
- ^ a b c d Centre for Commercialization of Regenerative Medicine "Lead Scientist: Gordon Keller"
- ^ University Health Network "Research Profile: Gordon Keller, PhD"
- ^ "Behind the Breakthrough Podcast - University Health Network Season 4 - Dr. Gordon Keller" (PDF). Retrieved 14 December 2023.
- ^ The Globe and Mail "Saskatchewan native Dr. Gordon Keller, a leader in regenerative medicine"
- ^ University of Saskatchewan "Honorary Doctor of Science - Gordon Keller"
- ^ Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G (1998). "A common precursor for hematopoietic and endothelial cells". Development. 125 (4): 725–732. doi:10.1242/dev.125.4.725. PMID 9435292.
- ^ Han S, Dziedzic N, Gadue P, Keller GM, Gouon-Evans V (2011). "An endothelial cell niche induces hepatic specification through dual repression of Wnt and Notch signaling". Stem Cells. 29 (2): 217–228. doi:10.1002/stem.576. PMC 3437666. PMID 21732480.
- ^ Nostro MC, Sarangi F, Ogawa S, Holtzinger A, Corneo B, Li X, Micallef SJ, Park IH, Basford C, Wheeler MB, Daley GQ, Elefanty AG, Stanley EG, Keller G (2011). "Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells". Development. 138 (5): 861–871. doi:10.1242/dev.055236. PMC 3035090. PMID 21270052.
- ^ Kattman SJ, Huber TL, Keller GM (2006). "Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages". Developmental Cell. 11 (5): 723–732. doi:10.1016/j.devcel.2006.10.002. PMID 17084363.
- ^ Craft AM, Ahmed N, Rockel JS, Baht GS, Alman BA, Kandel RA, Grigoriadis AE, Keller GM (2013). "Specification of chondrocytes and cartilage tissues from embryonic stem cells". Development. 140 (12): 2597–2610. doi:10.1242/dev.087890. PMID 23715552.
- ^ Kennedy M, Awong G, Sturgeon CM, Ditadi A, LaMotte-Mohs R, Zúñiga-Pflücker JC, Keller G (2012). "T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures". Cell Reports. 2 (6): 1722–1735. doi:10.1016/j.celrep.2012.11.003. PMID 23219550.
- ^ Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G (2014). "Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells". Nature Biotechnology. 32 (6): 554–561. doi:10.1038/nbt.2915. PMC 4152856. PMID 24837661.
- ^ "Development: Editorial Board".